Merck Sharp & Dohme Ltd, Merck & Company, Merck Res Labs

Activity: Visiting an external institutionProfessional

Description

Scoring of the PD-L1 (22C3) assay in triple negative breast cancer MSD/Merck, Trainer.
Training other pathologists to score the PD-L1 (22C3) assay for triple negative breast cancer.
Period11-May-2022
VisitingMerck Sharp & Dohme Ltd, Merck & Company, Merck Res Labs
Degree of RecognitionNational